A substantial advancement in diabetes care is emerging with the approval of tirzepatide at a dosage of 45mg. This innovative formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, https://deaconfvef930434.rimmablog.com/39604582/groundbreaking-approach-tirzepatide-dose-for-glucose-control